Results 171 to 180 of about 83,228 (255)

Temporal Interference Stimulation Modulates Resting State Functional Connectivity of Motor Circuit in Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background Transcranial temporal interference stimulation (TIs) targeting the subthalamic nucleus (STN) is a novel noninvasive neuromodulation approach with potential to improve motor symptoms in Parkinson's disease (PD). However, its underlying neuroimaging mechanisms remain unclear.
Yongxin Xu   +19 more
wiley   +1 more source

Health-related quality of life in remitted psychotic depression. [PDF]

open access: yesJ Affect Disord, 2019
Bingham KS   +11 more
europepmc   +1 more source

Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background SUNRISE‐PD was a dose‐escalating, phase 1/2 study investigating a second‐generation lentiviral vector gene therapy delivering the genes for dopamine synthesis (OXB‐102) to treat Parkinson's disease (PD). The trial was prematurely terminated due to insolvency of the sponsor.
Simon Rowe   +19 more
wiley   +1 more source

Greater Motor and Nonmotor Burden at Diagnosis Is Associated With Amyloid Copathology in Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background Concurrent Alzheimer's disease pathology is increasingly recognized as a poor prognostic factor in Parkinson's disease (PD), yet reliable clinical indicators for early identification of AD copathology remain poorly established.
Han Kyu Na   +11 more
wiley   +1 more source

Cannabis‐Based Oil for Pain and Other Non‐Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial

open access: yesMovement Disorders, EarlyView.
Abstract Background There is a lack of treatments for non‐motor symptoms (NMS) in Parkinson's disease (PD). Objective To assess the safety and effectiveness of an oral Cannabis sativa L. extract on pain and other NMS of PD. Methods This phase II, randomized, placebo‐controlled trial evaluated a formulation containing cannabidiol (CBD; 96 mg/ml) and Δ9 ...
Gabriel T. Kubota   +14 more
wiley   +1 more source

Apathy in Lewy Body Disorders: A Position Paper

open access: yesMovement Disorders, EarlyView.
Abstract Apathy is one of the most prevalent and disabling non‐motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional outcomes, yet remains ...
Jaime Kulisevsky   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy